Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Triamcinolone acetonide aqueous intranasal - Sanofi

Drug Profile

Triamcinolone acetonide aqueous intranasal - Sanofi

Alternative Names: Nasacort; Nasacort AQ; Nasacort® Allergy 24HR Nasal Spray; Triamcinolone acetonide water-based intranasal - Sanofi; XRG 5029

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Pregnadienes; Small molecules
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Perennial allergic rhinitis; Seasonal allergic rhinitis

Most Recent Events

  • 10 Jul 2017 Sanofi completes in the phase III NASANIF trial for Perennial allergic rhinitis (NCT03317015)
  • 12 Jun 2015 Non-prescription aqueous intranasal triamcinolone acetonide licensed to PENDOPHARM for commercialisation in Canada
  • 11 Oct 2013 The US FDA approves Nasacort® as over-the-counter (OTC) product for treatment of Seasonal allergic rhinitis and Perennial allergic rhinitis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top